No Data
No Data
Lobe Sciences Provides Company Review of 2023
Lobe Sciences Provides Update on L-130 Clinical Program
Lobe Sciences Provides Update on L-130 Oral Psilocin Compound
Biopharmaceutical company Lobe Sciences Ltd. (LOBE.CSE), on Tuesday announced its lead clinical asset, L-130, a proprietary stabilized psilocin conjugate drug candidate, recently surpassed the 12-mon
Lobe Sciences Appoints CFO
Lobe Sciences Ltd. (LOBE.CSE) said Monday that it has named Mathew Lee chief financial officer of the company. Lee currently serves as president of Manning Lee Management Ltd., a management consulting
Lobe Sciences Amends Terms of Altemia Share Purchase Agreement
Lobe Sciences Ltd. (LOBE.CSE), a North American biopharmaceutical company committed to discovering and developing patient-focused medicines for Orphan and Rare diseases, overnight Thursday said that i
Lobe Sciences, Ltd. Provides Update on Vitamind
Vancouver, British Columbia--(Newsfile Corp. - April 21, 2023) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a North American Biopharmaceutical Company committed to discov